EVA1C Is a Potential Prognostic Biomarker and Correlated With Immune Infiltration Levels in WHO Grade II/III Glioma

Abstract

BackgroundImmunotherapy is an effective therapeutic approach for multiple human cancer types. However, the correlations between EVA1C and patients’ prognosis as well as immune infiltration remain obscure. Herein, we employed transcriptomic and clinical data extracted from two independent databases to systematically investigate the role of EVA1C in the oncological context.MethodsThe differential expression of EVA1C was analyzed via TCGA and Oncomine databases. We evaluated the influence of EVA1C on clinical prognosis using Kaplan-Meier plotter. We then used the expression profiler to calculate stromal score, immune score, and ESTIMATE score based on the ESTIMATE algorithm. The abundance of infiltrating immune cells was calculated via TIMER. The correlations between EVA1C expression and immune infiltration levels were analyzed in two independent cohorts.ResultsIn patients with World Health Organization (WHO) grade II/III glioma, high EVA1C expression was associated with malignant clinicopathological features and poor overall survival in both cohorts. EVA1C expression was positively associated with immune infiltration levels of B cell, CD4+ T cell, neutrophil, macrophage, and dendritic cells (DCs). Besides, EVA1C expression strongly correlated with diverse immune marker sets. And the predictive power of EVA1C was better than that of other indicators in predicting high immune infiltration levels in glioma.ConclusionsFor the first time, we identified the overexpression of EVA1C in glioma, which was tightly correlated with the high infiltration levels of multiple immune cells as well as poor prognosis. Meanwhile, EVA1C might be a potential biomarker for predicting high immune infiltration in WHO grade II/III gliomas.

PODNL1 Methylation Serves as a Prognostic Biomarker and Associates with Immune Cell Infiltration and Immune Checkpoint Blockade Response in Lower-Grade Glioma

“…Increased immune cell infiltration levels are linked to heightened tumor aggressiveness in a range of cancers including breast cancer, kidney renal clear cell carcinoma, uveal melanoma, pancreatic cancer, and osteosarcoma [41][42][43][44][45][46][47][48]. In gliomas, including LGG, increased immune cell infiltration levels showed poor prognosis and more aggressive phenotypes [21,22,[49][50][51][52][53][54][55][56][57]. Thus, we report that low PODNL1 methylation, specifically of CpG sites cg07425555, cg26969888, cg18547299, and cg24354933, may be a key factor in the modulation of immune infiltrates in the LGG tumor microenvironment, affecting its aggressiveness and prognosis.…”

Microfibrillar-associated protein 2 is a prognostic marker that correlates with the immune microenvironment in glioma

“…The visual prediction model on which these findings are based has been reported to exhibit strong predictive value ( Qu et al, 2021b ). Recent progress in sequencing technology has promoted in-depth investigations into the molecular diagnosis of gliomas, revealing several genetic biomarkers ( Hu and Qu, 2021 ; Mao et al, 2022 ). The diagnostic and prognostic value of biomarkers in glioma was confirmed, and some biomarkers were used to guide the diagnosis and treatment of glioma in the fifth edition of the classification of central nervous system tumors released by WHO in 2021 ( Louis et al, 2021 ).…”

H2B gene family: A prognostic biomarker and correlates with immune infiltration in glioma

“…Pancancer analysis is also an important part of this article. In previous studies such as hu et al (67) and qu et al (68), they discussed the relationship between biomarkers and glioma from the perspective of immunity and methylation, respectively. But the fly in the ointment is the lack of a pan-cancer analysis, and the lack of experimental data to draw conclusions.…”